GlassScriptPhysician profile
Hesham Yasin
NPI 1710356720
$716.64
in general payments reported to CMS, 2019-2025
14 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.52 · 2024: $76.74 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $123.36 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $107.63 | 2025 | |
| Medtronic, INC. | $99.13 | 2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $88.50 | 2025 | Yorvipath |
| Novo Nordisk INC | $76.74 | 2024 | |
| Amgen INC. | $38.80 | 2025 | Evenity, Tepezza |
| Insulet Corporation | $31.29 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $29.92 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $29.52 | 2022 | |
| Sequel Med Tech, LLC | $22.58 | 2025 | Twiist |
| Sandoz INC. | $19.87 | 2025 | Wyost, Jubbonti |
| Lilly USA, LLC | $18.19 | 2025 | Jardiance |
| Tandem Diabetes Care, INC. | $16.55 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $14.56 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesham Yasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.